Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03981159
Other study ID # ExCiTE-A-17-0020
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2017
Est. completion date November 15, 2017

Study information

Verified date June 2019
Source University of Genova
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study was to examine the effects of exercise training on physical function and biochemical markers in elderly Alzheimer's disease patients.


Description:

Alzheimer's disease is a neurodegenerative disease characterized by progressive and irreversible degeneration of nerve cells. The loss of these cells leads to the continuous decline in muscle function with alterations in biochemical and haematological parameters. The objective of this study was to examine the effects of exercise training on physical function and biochemical markers in elderly Alzheimer's disease patients.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date November 15, 2017
Est. primary completion date July 1, 2017
Accepts healthy volunteers No
Gender All
Age group 80 Years to 90 Years
Eligibility Inclusion Criteria:

- Subjects with official diagnosis of Alzheimer's disease;

- Subjects with MMSE higher than12.

Exclusion Criteria:

• Subjects with MMSE below 12 (indicating severe dementia and impairment).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Physical training
Physical training for three months, twice per week (60 minutes per session).

Locations

Country Name City State
Italy University of Genova Genoa

Sponsors (1)

Lead Sponsor Collaborator
University of Genova

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tinetti test The 3-likert test assesses balance and gait abilities with an individual sitting in an armless chair, rising up, staying standing, turning 360° and then sitting back down. Gait is scored over 12 and balance is scored over 16, totalling 28 points. Approximately 10-15 minutes
Primary Berg Balance Scale The 14-item 5-likert (from 0 to 4) scale objectively determines a patient's balance ability during a series of predetermined tasks. Scores of each item are summed up: the total score ranges from 0 to 56. The lowest the score the lowest is the level of function, the highest the score the highest is the level of function. Approximately 20 minutes
Primary 6-minute walking test This test is a sub-maximal exercise used to evaluate aerobic capacity and endurance. 6 minutes
Primary Timed up and go test The test measures abilities of a patient initially in a seated position The patient is then asked to stand up up, walk 3 meters, turn around, walk back to the chair and sit down. Approximately 14 seconds
Primary "Walking While Talking" test This test is a dual-task test, consisting in walking while reciting the alphabet or alternate letters of the alphabet. Approximately 1 minute
Primary Red blood cell count Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary White blood cell count Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Hemoglobin Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Platelet count Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Hematocrit Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Triglycerides Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Cholesterol Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Total bilirubin Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary AST (aspartate aminotransferase) Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary ALT (alanine aminotransferase) Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Blood pressure Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Creatinine Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Urea Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Glucose Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Sodium Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Calcium Assessed with routine blood/biochemical assays Approximately 10-15 minutes
Primary Potassium Assessed with routine blood/biochemical assays Approximately 10-15 minutes
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A